Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (40% of 2020 sales), microbiology (30%), immunoassays (15%), and industrial applications (about 15%). North America accounts for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (33%), Asia-Pacific (16%), and Latin America (6%). BioMerieux is headquartered in Marcy-l'Etoile, France.
Lyon, 69280, France